How much does imitation adagraxibu cost?

Adagrasib is a drug that targets specific cancer mutations and belongs to a class of drugs called KRAS G12C inhibitors. KRAS G12Cmutation is a common cancer mutation, especially in lung cancer, accounting for about KRAS mutations20%. KRASGene mutations often lead to excessive proliferation and growth of tumor cells, making them an important target for cancer treatment.

Since adagrasib has not yet been launched in China, patients cannot purchase it directly domestically and must resort to overseas channels. At present, the original adagrasibu drug in foreign countries is mainly produced in the United States, but the price is extremely expensive, reaching more than 180,000 yuan, which makes it difficult for ordinary families to afford it. However, the good news is that generic drugs have recently become available abroad. For example, the generic drug of adagrasibu produced by Lucius in Laos costs about 4,000 to 5,000 yuan per box, which is significantly lower than the price of the original drug. After testing, the generic drug is basically consistent with the original drug in terms of drug ingredients.

Adagrasib was developed to target this challengingKRAS mutation. Its development marks a breakthrough in long-standing efforts to target KRAS mutations. Traditionally, KRAS mutations have been considered difficult to target, so treating this type of cancer has been a difficult task.

Compared with traditional chemotherapy drugs, adagrasib has a more precise mechanism of action. It can specifically inhibit the KRAS G12C mutation, thereby blocking the growth signals of cancer cells and promoting apoptosis or stopping proliferation of cancer cells. This targeting allows adagrasib to more effectively inhibit tumor growth during treatment, while reducing damage to healthy tissue and reducing the toxic and side effects of treatment.

Clinical trial results show that adagrasib has shown good efficacy and safety in the treatment of KRAS G12C mutated lung cancer patients. Some studies have even shown that it may be equally effective against the KRAS G12C mutation in other cancer types, raising the possibility of wider application.